CTRL WRK Launches in the ServiceNow Store, Transforming Safety and Efficiency
BOSTON--(BUSINESS WIRE)-- CTRL WRK, the groundbreaking AI-powered Control of Work solution, is now officially available in the ServiceNow Store, setting a new standard for how enterprises manage Lockout Tagout (LOTO) procedures. Built natively on the trusted ServiceNow ® platform, CTRL WRK simplifies, streamlines, and supercharges safety-critical operational risk management with powerful automation and deep industry expertise.
CTRL WRK harnesses the power of artificial intelligence to eliminate inefficiencies, reduce operational risk, and empower teams with real-time insights. With an intuitive interface and seamless integration into existing ServiceNow environments, CTRL WRK transforms the traditionally manual, error-prone LOTO process into a smart, scalable, and compliant digital workflow.
CTRL WRK is co-founded by Aaron Callaway, a seasoned entrepreneur and repeat founder who previously built Fairchild Resiliency Systems, which was successfully acquired by ServiceNow in 2019. With over a decade of experience in the ServiceNow ecosystem and a proven track record of innovation, Callaway is once again at the forefront of platform-native solutions that reshape enterprise operations.
"We're thrilled to bring CTRL WRK to the ServiceNow Store and into the hands of enterprise users who are ready for what's next,' said Aaron Callaway, Cofounder and Chairman of CTRL WRK. 'By combining cutting-edge AI, our team's unmatched domain expertise in Control of Work, we're delivering a truly game-changing solution to a critical area of enterprise safety and operations."
What sets CTRL WRK apart is its deep domain expertise: the team brings over 20 years of hands-on experience in Operational Risk and Lockout Tagout practices across highly regulated industries like utilities and oil & gas. This knowledge, combined with ServiceNow's scalable infrastructure and AI capabilities, makes CTRL WRK the most advanced and dependable LOTO solution available today.
With CTRL WRK, organizations gain:
AI-powered Lockout Tagout isolation planning and risk identification using documentation such as P&IDs.
Real-time tracking & visibility of all LOTO & Permit work in your operations.
Fully configurable forms, fields and workflow – designed to conform to your business process needs.
Mobile app to support maintenance and operations in the field.
Seamless integration with 3rd party solutions using ServiceNow's Data Workflow Fabric.
CTRL WRK is now available to all ServiceNow customers directly from the ServiceNow Store. Early adopters are already seeing significant improvements in compliance, operational uptime, and user adoption.
About CTRL WRK
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Yahoo
16 hours ago
- Yahoo
3 growth stocks I've bought for the ‘AI agent' revolution
As a long-term investor, I tend to focus on big, powerful investment themes. And one theme I'm really excited about today is the emergence of 'AI agents' – software that can perform business tasks autonomously. I believe the investment potential here is enormous. With that in mind, here are three growth stocks I've bought for the agentic AI revolution. My number one play on AI agents today is software company Salesforce (NYSE: CRM). It has a product called Agentforce and it's having a lot of success with it. Indeed, since its launch in October last year, the company has signed over 8,000 customers. Of these, around half are now paying for the service. The main reason I'm bullish here is that Agentforce integrates really well with Salesforce's apps and data services (Data Cloud and Tableau Next). This is important – without the right data, agents are likely to be useless. I'll point out that ServiceNow's agentic AI offering also integrates well with data and apps. So, competition from this firm is a risk. However, I like the risk-reward proposition here at today's share price and valuation. Salesforce trades on a price-to-earnings (P/E) ratio of just 23. I believe the stock offers value at present and is worth considering. Microsoft (NASDAQ: MSFT) is well known for its generative AI capabilities (it's a part-owner of ChatGPT-owner OpenAI). What a lot of investors don't realise, however, is that this company is also a major player in the agentic AI space. Today, it offers a range of services designed to help developers/organisations build and deploy agents to increase business productivity. For example, Azure AI Foundry Agent Service allows professional developers to build specialised agents to handle complex business tasks. I was buying this growth stock a few months ago when it was near $350. It's now at $480, so doesn't look as attractive as it did back then. That said, I think it's still worth considering for the long term (especially on a 5%-10% pullback). While competition from other cloud computing giants such as Amazon and Alphabet is a risk, I believe this stock has bags of potential. Finally, I think CrowdStrike (NASDAQ: CRWD) could be a major player in the agentic AI revolution. It's one of the world's leading cybersecurity companies. It offers a solution called Charlotte AI, which CEO George Kurtz refers to as the company's agentic security analyst. This is designed to transform threat detection and response by bringing automation and autonomous reasoning to cybersecurity operations. CrowdStrike should also benefit from other companies' rollout of AI agents. Given that they typically have access to massive amounts of data, they are going to significantly increase the surface area of IT that needs to be protected. Now, this stock is the riskiest of the three. That's because it's a much younger company (meaning it's a little more unproven) and doesn't have a lot of profits at this stage. It has also had a huge run this year, rising over 40%. I still believe it's worth considering, but I think investors are better off waiting for a pullback before buying. The post 3 growth stocks I've bought for the 'AI agent' revolution appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Edward Sheldon has positions in Alphabet, Amazon, CrowdStrike, Microsoft, and Salesforce. The Motley Fool UK has recommended Alphabet, Amazon, CrowdStrike, Microsoft, ServiceNow, and Salesforce. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
